Outcome of Board Meeting Held On October 17, 2026

October 17, 2026 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Limited First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No. C/1, ‘G’ Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai 400001 Bandra East Mumbai 400051 Fax No.2272 3121/2037/2039 Fax No.2659 8237/8238 Stock Code: 543213 Stock Code: ROSSARI Dear Sir/Madam, Sub.: Outcome of Board Meeting held on Saturday, October 17, 2026 Ref.: Compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. With regards to the captioned matter and in compliance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (“Listing Regulations”), as amended, this is to inform you that at the meeting of the Board of Directors of the Company (“the Board”) which commenced at 05:48 P.M. and concluded at 06:30 P.M. today i.e. Saturday, October 17, 2026, the Board of Directors of the Company have inter alia approved the following: 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026 Copy of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026 along with Statement of Assets and Liabilities and Cash Flow Statement for the half year ended September 30, 2026 are enclosed herewith. The aforesaid results were reviewed by the Audit Committee and subsequently, approved and taken on record by the Board of Directors of the Company. We would further like to inform that the Statutory Auditors of the Company have subjected the aforesaid results to “Limited Review” and the same are enclosed herewith. 2. Approval for leasing of land for setting-up of greenfield manufacturing facilities by Rossari International Limited Company, wholly owned subsidiary of the Company Further, to our intimation dated January 17, 2026, the Board has accorded its approval for the leasing of land by Rossari International Limited Company, a wholly owned subsidiary, for setting up of greenfield manufacturing facility in Kingdom of Saudi Arabia (KSA). Detailed project plan, including nature of the project and overall investment, once finalised will be placed before the Board for approval. Accordingly, the Company shall make further disclosures as required pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as and when there are any material developments. The same may please be taken on record and suitably disseminated to all concerned. Thanking you, Yours Sincerely, For Rossari Biotech Limited Parul Gupta Company Secretary & Head - Legal Membership No.: A38895 Encl.: as above Walker Chandiok &.Co LLP Walker Chandiok & Co LLP 42nd Floor, Building Commerz Ill, International Business Park, Oberoi Garden City, Off Western Express Highway, Goregaon (East), Mumbai-400063 T +91 22 6626 2699 Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Rossari Biotech Limited 1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Rossari Biotech Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), its associate and joint venture (refer Annexure 1 for the list of subsidiaries, associate and joint venture included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 1 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable. 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any mate_,,r,::i:::,;:.-a~,.__ misstatement. Chartered Accounlants Walker Chandiok & Co LLP is registered with limited liability with identification Offices in Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Dehradun, Goa, Gurugram. Guwahati. Hyderabad, Indore, number AAC-2085 and has its registered Kochi. Kolkata, Mumbai, New Delhi, Noida and Pune office at L-41, Connaught Circus, Outer Circle. New Delhi, 110001, India Rossari Biotech Limited Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) 5. We did not review the interim financial results of five subsidiaries included in the Statement, whose financial results reflect total assets off 13,130.97 million as at 30 September 2026, and total revenues off 5,231.06 million and f 10,801.73 million, total net profit after tax off 106.23 million and f 189.94 million, total comprehensive income of f 106. 73 million and f 190. 93 million, for the quarter and six months period ended on 30 September 2026, respectively, and cash flows (net) off (20.14) million for the six months period ended 30 September 2026, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of f 4.09 million and f 7.79 million and total comprehensive income off 4.09 million and f 7.79 million, for the quarter and six-months period ended on 30 September 2026, respect [Showing first 8,000 characters — download PDF for full document]